As of June 30, 2025, the Company had cash and cash equivalents, and short-term investments of $165.6 million. The Company expects that its existing cash and cash equivalents, and short-term investments, together with the net proceeds from the August 2025 underwritten offering, will be sufficient to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2028, including through a randomized Phase 2 trial of givastomig.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I MAB (ADS) options imply 11.8% move in share price post-earnings
- I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
- I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
- 3 Penny Stocks to Watch Now, 8/5/25
- I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline